转移性结肠癌的全身治疗：新前沿
Systemic Therapy for Metastatic Colon Cancer: New Frontiers.
作者信息
Pumpalova Yoanna S
机构信息
Division of Hematology and Oncology, Department of Internal Medicine, Columbia University Irving Medical Center, New York, New York.
出版信息
Clin Colon Rectal Surg. 2024 Jun 25;38(3):229-236. doi: 10.1055/s-0044-1787826. eCollection 2025 May.
Abstract
We have made steady gains in improving overall survival in patients with metastatic, unresectable, colon cancer in the last 5 to 10 years. The backbone of systemic treatment for most patients remains combination chemotherapy, but the field is becoming increasingly biomarker driven, with exciting new targeted therapies on the horizon. This review is organized in sections corresponding to currently relevant biomarkers in colon cancer and will summarize first-, second-, and third-line standard of care for metastatic, unresectable, colon cancer. The last section is intended to introduce the reader to promising agents and novel therapeutic strategies currently under investigation.
摘要
在过去5到10年中，我们在改善转移性、不可切除结肠癌患者的总生存率方面取得了稳步进展。对大多数患者来说，全身治疗的主要方法仍然是联合化疗，但该领域正越来越多地由生物标志物驱动，有令人兴奋的新靶向疗法即将出现。本综述按与结肠癌当前相关的生物标志物进行章节编排，将总结转移性、不可切除结肠癌的一线、二线和三线标准治疗方案。最后一部分旨在向读者介绍目前正在研究的有前景的药物和新型治疗策略。
相似文献
1
Systemic Therapy for Metastatic Colon Cancer: New Frontiers.转移性结肠癌的全身治疗：新前沿
Clin Colon Rectal Surg. 2024 Jun 25;38(3):229-236. doi: 10.1055/s-0044-1787826. eCollection 2025 May.
2
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
3
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
4
Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.用于转移性结直肠癌的表皮生长因子受体（EGFR）抑制剂
Cochrane Database Syst Rev. 2017 Jun 27;6(6):CD007047. doi: 10.1002/14651858.CD007047.pub2.
5
A systematic overview of chemotherapy effects in colorectal cancer.结直肠癌化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):282-308. doi: 10.1080/02841860151116367.
6
Chemotherapy for advanced gastric cancer.晚期胃癌的化疗
Cochrane Database Syst Rev. 2017 Aug 29;8(8):CD004064. doi: 10.1002/14651858.CD004064.pub4.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
8
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.成人止吐药预防中度或高度致吐性化疗引起的恶心和呕吐：网状荟萃分析。
Cochrane Database Syst Rev. 2021 Nov 16;11(11):CD012775. doi: 10.1002/14651858.CD012775.pub2.
9
A systematic overview of chemotherapy effects in breast cancer.乳腺癌化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):253-81. doi: 10.1080/02841860151116349.
10
Systemic therapy for treating locoregional recurrence in women with breast cancer.治疗乳腺癌女性局部区域复发的全身治疗
Cochrane Database Syst Rev. 2001;2001(4):CD002195. doi: 10.1002/14651858.CD002195.
本文引用的文献
1
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.仑伐替尼联合帕博利珠单抗对比既往治疗的转移性结直肠癌标准治疗：LEAP-017 研究的随机、开放标签、III 期研究的最终分析。
J Clin Oncol. 2024 Aug 20;42(24):2918-2927. doi: 10.1200/JCO.23.02736. Epub 2024 Jun 4.
2
Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort.卡博替尼联合度伐利尤单抗治疗化疗耐药结直肠癌（CRC）的 II 期临床试验的临床和生物标志物结果：CAMILLA CRC 队列。
Nat Commun. 2024 Feb 20;15(1):1533. doi: 10.1038/s41467-024-45960-2.
3
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated G12C.索托拉西布联合帕尼单抗治疗携带 G12C 突变的难治性结直肠癌。
N Engl J Med. 2023 Dec 7;389(23):2125-2139. doi: 10.1056/NEJMoa2308795. Epub 2023 Oct 22.
4
Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes.抗 EGFR 治疗对 HER2 阳性转移性结直肠癌的影响：临床结局的系统文献回顾和荟萃分析。
Oncologist. 2023 Oct 3;28(10):885-893. doi: 10.1093/oncolo/oyad200.
5
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.呋喹替尼对比安慰剂用于治疗难治性转移性结直肠癌患者（FRESCO-2）：一项国际、多中心、随机、双盲、III 期研究。
Lancet. 2023 Jul 1;402(10395):41-53. doi: 10.1016/S0140-6736(23)00772-9. Epub 2023 Jun 15.
6
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.DESTINY-CRC01 研究评估曲妥珠单抗 deruxtecan 在人表皮生长因子受体 2（HER2）表达转移性结直肠癌患者中的最终结果。
Nat Commun. 2023 Jun 7;14(1):3332. doi: 10.1038/s41467-023-38032-4.
7
The Therapeutic Landscape for -Mutated Colorectal Cancers.KRAS 突变型结直肠癌的治疗前景
Cancers (Basel). 2023 Apr 19;15(8):2375. doi: 10.3390/cancers15082375.
8
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.图卡替尼联合曲妥珠单抗治疗化疗耐药、HER2 阳性、RAS 野生型不可切除或转移性结直肠癌（MOUNTAINEER）：一项多中心、开放标签、2 期研究。
Lancet Oncol. 2023 May;24(5):496-508. doi: 10.1016/S1470-2045(23)00150-X.
9
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.替氟尿苷替匹嘧啶与贝伐珠单抗治疗难治性转移性结直肠癌
N Engl J Med. 2023 May 4;388(18):1657-1667. doi: 10.1056/NEJMoa2214963.
10
Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study.瑞戈非尼联合纳武利尤单抗治疗错配修复功能正常/微卫星稳定的转移性结直肠癌患者：一项单臂、开放标签、多中心2期研究。
EClinicalMedicine. 2023 Apr 6;58:101917. doi: 10.1016/j.eclinm.2023.101917. eCollection 2023 Apr.
Zotero 插件